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INTRODUCTION
Among the different types of brain tumors, 
glioblastoma multiforme  (GBM) is the most aggressive 
and recurrent one. GBM progression and recurrence often 
correlated with the existence of cancer stem cells (CSC), 
a small population of tumor initiating cells that have an 
enhanced resistance to radio- and chemotherapy [1].
Different molecular signaling pathways are 
involved in the uncontrolled GBM growth. Few years 
ago, the Cancer Genome Atlas (TCGA) proposed a 
gene expression-based classification of GBM: classical/
EGFR+, proneural/PDGFR +, and mesenchymal/NF1+ 
[2, 3]. Such a classification has been crucial to explain 
the biology and the heterogeneous nature of GBM, but 
its prognostic value was rather limited. Recently, few 
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ABSTRACT
The invasive and lethal nature of Glioblastoma multiforme (GBM) necessitates 
the continuous identification of molecular targets and search of efficacious therapies 
to inhibit GBM growth. The GBM resistance to chemotherapy and radiation it is 
attributed to the existence of a rare fraction of cancer stem cells (CSC) that we 
have identified within the tumor core and in peritumor tissue of GBM. Since Notch1 
pathway is a potential therapeutic target in brain cancer, earlier we highlighted 
that pharmacological inhibition of  Notch1 signalling  by  γ-secretase inhibitor-X 
(GSI-X), reduced cell growth of some c-CSC than to their respective p-CSC, but 
produced negligible effects on cell cycle distribution, apoptosis and cell invasion. 
In the current study, we assessed the effects of Hes1-targeted shRNA, a Notch1 
gene target, specifically on GBM CSC refractory to GSI-X. Depletion of Hes1 protein 
induces major changes in cell morphology, cell growth rate and in the invasive ability 
of shHes1-CSC in response to growth factor EGF. shHes1-CSC show a decrease of 
the stemness marker Nestin concurrently to a marked increase of neuronal marker 
MAP2 compared to pLKO.1-CSC. Those effects correlated with repression of EGFR 
protein and modulation of Stat3 phosphorylation at Y705 and S727 residues. In the 
last decade Stat3 has gained attention as therapeutic target in cancer but there is 
not yet any approved Stat3-based glioma therapy. Herein, we report that exposure 
to a Stat3/5 inhibitor, induced apoptosis either in shHes1-CSC or control cells. Taken 
together, Hes1 seems to be a favorable target but not sufficient itself to target GBM 
efficaciously, therefore a possible pharmacological intervention should provide for 
the use of anti-Stat3/5 drugs either alone or in combination regimen.
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reports suggest a mechanism-based classification that 
point to the identification of new prognostic markers not 
captured by existing classifications.  Fifty percent of all 
GBM tumors present in the TCGA can be classified into 
high miR-21/low Sox2 or low miR-21/high Sox2 subtypes 
[4]. This classification can predict patient survival better 
than the currently used parameters. Recently, it has been 
reported that GBM progression and recurrence of a subset 
of tumors is associated with an increase of mesenchymal 
markers staining and aggressive behavior [5]. Notably, a 
bioinformatics analyses revealed a prominent role of Stat3 
in GBM mesenchymal subtype and suggest an association 
between Notch1 and Stat3 signaling in this specific 
subtype [6]. Recently, it has been reported that MLK4 
dependent-NF-κB activation induced a mesenchymal 
trans-differentiation and radio-resistance in GBM CSC, 
assigning to MLK4-NF-κB signaling axis a potential 
prognostic value useful for GBM with a mesenchymal 
signature [7, 8].
The Notch pathway, a therapeutic target in cancer, 
is known to play a crucial role in controlling cancer stem 
cell renewal, differentiation, apoptosis and angiogenesis 
[9–11].  The Notch pathway encompasses four types of 
receptors (Notch1, 2, 3, 4), and five membrane proteins 
ligands that include Delta-like ligands (DLL), 1, 2, 3, 
and Serrate/Jagged (JAG) 1 and 2.  Binding of Notch 
ligands, and receptors located on the surfaces of neighbor 
cells, trigger the activation of cleavage enzymes such as 
ADAM10/TACE, and presenilin-dependent γ-secretase 
protease complex [12]. Following its cleavage, the Notch 
Intracellular Domain (NICD) is released into the nucleus, 
binds to transcription factor RBP-Jκ, and becomes an 
active transcriptional complex that induce the transcription 
of Notch target genes: Hairy Enhancer of Split 1 (HES1), 
HES-related proteins (HEY), p21 (CDKN1A), Cyclin 
D1(CCDN1),  c-myc (MYC), BCL2,  DTK1 (Deltex1) 
and NF-κB2 [13–16].
Beside Notch signaling, receptors tyrosine kinases 
(RTKs) such as epidermal growth factor receptor (EGFR) 
and platelet-derived growth factor receptor (PDGFR) are 
important contributors to GBM initiation and progression. 
RTKs activation through binding to specific ligands 
induces its auto-phosphorylation and activation of MAP 
kinase, PI3K/Akt, Jak/Stat3 signaling [17–20].
The concept of molecular therapy for GBM depends 
on possible genetic or pharmacological manipulations 
of the key signaling pathways with an ultimate goal of 
attenuating or inhibiting GBM growth and angiogenesis 
[9]. Evidence have demonstrated that Notch1 regulates 
transcription of EGFR through p53 [21]. Previous studies 
proved that targeting of PDGFRβ or PDGFRα attenuated 
self-renewal, survival, growth, epithelial to mesenchymal 
transition and angiogenesis of GBM CSC [22, 16]. 
In the current study, we aim to continue our previous 
efforts to elucidate the complex interplay between 
the major signaling pathways that boost GBM CSC 
growth. Specifically, we have investigated the effects of 
lentiviral transduction of Hes1-targeted shRNA in GBM 
peritumor-derived CSC resistant to GSI-X. We report a 
significant decrease of cell growth rate, changes in cell 
cycle distribution, attenuation of stem cells features 
and induction to neuronal differentiation. Depletion 
of Hes1 downregulates EGFR protein and modulates 
Stat3 phosphorylation at Tyr-705 and Ser-727. Herein, 
we identified Stat as a potential therapeutic target for 
GBM, indeed we report that the treatment with a Stat3/5 
inhibitor, drives CSC to apoptosis. Taken together, our 
results provide a clear evidence that manipulation of Notch 
signaling pathways through inhibition of a downstream 
gene target, Hes1, is a favorable therapeutic strategy. 
Application of this strategy within the context of a more 
comprehensive multi-targeted pharmacological and/or 
genetic therapeutic regimen would expected to provide a 
more effective anti-GBM therapy.
RESULTS 
In this study, we investigated the effects of depletion 
of Hes1 expression, as one of the main target gene of 
Notch signaling, on the modulation of cell growth, 
differentiation, invasive ability and apoptosis of GBM 
CSC. GBM lesions were excised together with 1–2 cm 
from the tumor outer limit according to criteria previously 
provided [23]. Two types of CSC populations were derived 
from the excised GBM lesions: core-Cancer Stem Cells 
(c-CSC) and peritumor tissue-derived Cancer Stem Cells 
(p-CSC). Here, we concentrated specifically on a case 
of CSC (p-CSC1) that we previously demonstrated their 
marked resistance to apoptosis following their exposure to 
anti-Notch1/anti-EGFR drugs intervention [17].
Hes1-directed shRNA affects major functional 
cellular pathways
We highlighted the effects of Hes1-directed shRNA 
stably transduced in CSC by a lentiviral-based system 
(shHes1-CSC cl 7152 and 7153) vs control infected cells 
(pLKO.1-CSC) on key cellular pathways: Notch1 & 
RTKs signaling components, cell differentiation markers, 
cell cycle regulators, survival factors, and angiogenesis. 
Gene expression profile showed a significant down-
modulation of several components of Notch1 signaling 
in shHes1-CSC in comparison to pLKO.1-CSC such as: 
Hairy and Enhancer of Split-1 (HES1), HES-Related 
Protein 1 (HEY1), Jagged1 (JAG1), NOTCH1, Deltex1 
(DTK1), CyclinD1 (CCND1), Cyclin-Dependent Kinase 
Inhibitor 1 (CDKN1A), B-Cell Lymphoma-2 (BCL2) and 
BCL2-Like 1 (BCL2L1). The Delta Like Ligand 1 (DLL1) 
mRNA expression was similar between shHEs1-CSC 
clones and control cells (Figure 1A). Western blot assays 
confirmed the decrement of Hes1 and active Notch1 
(NICD1) (Figure 1B). Unexpectedly, CycD1 protein was 
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induced concurrently with p27, a cyclin-dependent kinase 
inhibitor that control the cell cycle progression at G0/G1. 
As a consequence of Hes1 depletion Survivin and Bcl-
X/L protein levels were down-modulated (Figure 1B). As 
Notch1 is known to be a regulator for neurogenesis and 
plays crucial role in other cell fate decisions, our study 
clearly showed the upregulation of neuronal and glial 
markers MAP2 and GFAP respectively, and repression 
of β-TubIII and Nestin proteins in shHes1-CSC vs 
pLKO.1-CSC (Figure 1B). Accordingly to Huang et al., 
the activity of Notch1 is essential for Stat3 activation in 
mouse embryonic stem cells (mESC), and the authors 
suggest the presence of a dynamic equilibrium of Stat3 
phosphorylation in Tyr705 (Y705) and Ser727 residues 
(S727) in the control of mESC fate. This prompted us to 
assess any change in Stat3 phosphorylation in shHes1-
CSC (Figure 1B). shHES1-CSC clones displayed a weak 
phosphorylation at Y705 and an increase at S727, that 
correlated with the transition from the multipotent state 
to neuronal commitment of shHes1-CSC and manifested 
with low Nestin/high MAP2 expression respect to control 
cells (Figure 1B and Figure 2A–2C). Finally, we reported 
that Hes1-directed shRNA suppressed EGFR protein and 
upregulated PDGFRβ, but not PDGFRα (Figure 1B, 1C).
Notch pathway is known to be indispensable 
for vascular development during embryogenesis and 
postnatal angiogenesis and accordingly, we evaluated 
gene expression of endothelial markers such as CD31/
CDH1 and the vascular endothelial cadherin (VE-CAD/
CDH5) and we found that those were significantly affected 
by Hes1 depletion at the protein (Figure 1B) and mRNA 
level (Figure 4B).
Targeting Hes1 expression decreases cell 
proliferation rate
To study the effects of Hes1 expression inhibition 
on cell proliferation we have used MTS assay. The clones 
7152 and 7153 of shHes1-CSC showed a decrease of the 
cell proliferation rate vs pLKO.1-CSC, which was more 
pronounced in clone 7153 (Figure 1D). These findings 
indicated that there was a negative correlation between 
Figure 1: Downmodulation of Hes1 expression affects Notch1 signaling, self-renewal, oncogenic signaling pathways 
and cell growth rate in shHes1-CSC. (A) RT-qPCR analyses reveal a significant decrease of Notch1 signaling components including 
conventional Hes1 targets. (B) Western blot analyses confirm the downmodulation of Notch1 signaling gene profile and highlight the neural 
differentiation of CSC via upregulation of MAP2 and GFAP and loss of Nestin. (C) Depletion of Hes1 diminishes the phosphorylation levels 
of Stat3 at Y705 but induces those at S727 residue. Furthermore, noteworthy are a remarkable reduction of EGFR protein the upregulation 
of PDGFRβ and the downmodulation of expression of angiogenic markers (CD31 and VE-cadherin). (D)  Knockdown of Hes1 expression 
was associated with a highly significant inhibition of the proliferation rate of shHes1-CSC clone 7152 and 7153 vs pLKO.1 cells. Data are 
expressed as mean ± SD (n = 3), and are representative of three independent experiments. We denote the significant difference between 
cell clones and control cells (***P ≤ 0.001).
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inhibition of Hes1 expression and GBM CSC proliferation, 
a finding that reinforce the importance of Notch signaling 
manipulation as a potential therapeutic target for GBM.
Targeting Hes1 expression promotes neuronal 
commitment and modulates cell cycle profile
Following culture, pLKO.1-CSC formed classical 
non-adherent neurospheres (Figure 2A). In contrast, 
at 6 hs post culturing, the shHes1-CSC were shown to 
be adhered to the culture dish.  At 48 hs post-culture, 
some of them exhibited a neuronal-like morphology 
with extended branched cytoplasmic processes (Figure 
2B–2C). Immunofluorescence assays performed in 
cell proliferation conditions revealed that MAP2 (a/b) 
positivity in both clones of shHes1-CSC (Figure 3D–3F) 
inversely correlated with Nestin staining as compared 
to pLKO.1-CSC (Figure 1B and Figure3A–3C). A 
quantitative analysis of the cells immunostained for Nestin 
and MAP2 reported that p-LKO.1-CSC are 25% ± 4.2 and 
5% ± 1.1 positives for Nestin and MAP2 respectively. In 
contrast, shHes1-CSC cl 7152 and cl 7153 are 9% ± 2.4 
and 12% ± 3.1 % positives for Nestin respectively; 
instead 30% ± 3.2 and 25% ± 5.1 of positivity for MAP2 
respectively. These findings might suggest a commitment 
of shHes1-CSC toward differentiation into neuronal 
lineage. In addition, we investigated the effects of Hes1 
depletion on the modulation of the cell cycle profile 
(Figure 2D–2F). The G1, G2/M, S phases distribution 
for pLKO.1-CSC was 41.10%, 19.86%, 39.04% and 
apoptosis 0.21%, respectively (Figure 2D). For shHes1-
CSC cl. 7152 was 56.12%, 21.81%, 22.07% and apoptosis 
0.21% respectively (Figure 2E). For shHes1-CSC cl. 7153 
it was 57.70%, 20.45%, 21.85% and 0.35% apoptosis, 
respectively (Figure 2F). These results showed that the 
knockdown of Hes1 expression induced a significant 
shifting of cells in G1 fraction, which correlated to the 
raising of p27 levels and the neuronal differentiation 
(Figure 1B and Figure 3D–3F).
Depletion of Hes1 impairs cell invasive ability in 
response to epidermal growth factor
The important effects induced by Hes1 depletion 
on expression of fundamental transmembrane receptors 
may have implications in CSC invasion. This prompted 
us to evaluate, in transwell assay, the invasive properties 
of shHes1-CSC vs pLKO.1-CSC in response to EGF, 
PDGFAA and PDGFBB growth factors. We revealed 
a significant increase of invasion of pLKO.1-CSC in 
response to EGF. Conversely, silencing of Hes1 inhibited 
EGF-induced cell invasion and downregulation of MMP-7 
and EGFR expression contributed to the reduced invasive 
ability of shHes1-CSC. MMP9 mRNA expression was 
identical among shHES1-CSC cell clones and pLKO. 
1-CSC (Figure 4B). We further demonstrated that PDGF-AA 
and PDGF-BB dispensed alone improved shHes1-CSC 
migration compared to stem medium and pLKO.1-
CSC (Figure 4A). Recent evidence have reported that 
Notch1 activation is associated with GBM proneural and 
mesenchymal subtypes, therefore by RTq-PCR analysis, 
we assessed whether well-known epithelial mesenchymal 
transition (EMT) genes were downregulated in shHes1-
CSC. In fact, we highlighted a significant mRNA 
down-modulation of TWIST1, Fibronectin1 (FN1) and 
Vimentin1 (VIM1) in shHes1-CSC, indicating a role 
of Notch1 in defining the molecular profile of GBM 
mesenchymal subtype (Figure 4B). 
A crosstalk between inflammatory mediators and 
Notch1 has been evidenced in colon cancer, glioma, 
cholangiocarcinoma and in macrophages activation. RTq-
PCR analyses reported a significant down-modulation of 
inducible nitric oxide synthase (NOS2), pro-inflammatory 
cytokines (interleukin-6/IL6), interleukin-1β/IL1B). 
Conversely, IL23 mRNA expression was similar between 
shHes1-CSC and pLKO.1-CSC (Figure 4B). 
STAT3/5 is essential for survival of shHes1-CSC 
and pLKO.1-CSC
The extensive detrimental effects produced by 
Hes1 depletion were not followed by CSC apoptosis. To 
reach this objective, we targeted Stat expression by using 
SH-4–54, a Stat3/5 small inhibitor. MTS assays were used 
to test the drug sensitivity of shHes1-CSC vs pLKO.1. 
shHes1-CSC were significantly sensitized at 0.5 µM of 
SH-4-54 compared to pLKO.1 after 1 day of treatment. 
Higher concentrations of SH-4-54 (2–5 µM) progressively 
prone CSC to cell death as seen by light microscope (data 
not shown) and MTS reduction output (Figure 5A). We 
used SH-4-54 at the intermediate dose, which reduced cell 
viability at fifty percent, to perform Western blots analysis. 
After 24 hs of SH-4-54 treatment, Stat3 and Stat5 proteins 
stability and activity were abolished (Figure 5B). SH-4-
54 treatment was able to induce Caspase-3 activation (19-
17 KDa) and PARP1 (116-89 KDa) fragments, and even 
anti-apoptotic signals such as P-Akt (S473) and P-Erk1/2 
(T202-Y204), Bcl2 and CyclinD1 declined drastically 
(Figure 5B).
Crenolanib is not effective in promoting 
apoptosis in shHes1-CSC
We previously reported that Crenolanib, a PDGFR 
inhibitor currently used in clinical trials to treat GBM, 
induced apoptosis at the same extent either in c-CSC1 or 
p-CSC1, circumventing the anti-Notch and anti-EGFR drug 
resistance. Herein, unexpectedly we reported that shHes1-
CSC were not sensitized to Crenolanib as did pLKO.1-CSC 
(Supplementary Figure 1). Western blot data disclosed a 
significant upregulation of oncogenic and survival signals 
such as PDGFRβ, Stat5 and Erk1/2,  and CyclinD1 
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in shHes1-CSC clones compared to pLKO.1-CSC 
(Supplementary Figure 1). Overall, our results revealed 
substantial differences in molecular pathways among the 
cell populations, and further studies are needed to better 
understand the signaling networks between these factors. 
DISCUSSION 
Notch signaling has been demonstrated to have a 
central role in hematopoietic cancers and solid tumors, 
included GBM [24]. In our study, depletion of Hes1 
inhibited proliferation rate of GBM CSC, which was more 
pronounced in shHes1-CSC cl. 7153 compared to pLKO.1-
CSC. The reduction of cell proliferation most likely was 
due to cell cycle inhibitor p27 upregulation which drives 
shHes1-CSC clones to G1 fraction of cell cycle. Our finding 
indicate the importance of Notch signaling manipulation 
as a potential therapeutic target for GBM. The results 
presented here are partially in agreement with those of Saito 
et al., who demonstrated that Notch pathway inhibition by 
DAPT, a γ-secretase inhibitor, attenuated proliferation and 
self-renewal of glioma-initiating cells (GIC) and induced 
both neuronal and astrocytic differentiation [25]. In our 
work, the premise was how to explain the poor response of 
GBM CSC to GSI-X treatment with high Notch1 signaling 
expression. Conversely, Saito et al. reported that proneural 
GIC characterized by active Notch signaling components, 
i.e., Notch1, Notch3, Hes1, MAML1, Dll3, Jag2, and 
several other, exhibited great sensitivity to GSI treatment. 
Here, we strived to elucidate the mechanism(s) and the 
underpinning intracellular signaling pathways by which 
knockdown of Hes1 expression inhibits proliferation and 
attenuated invasive ability of GBM CSC. The knockdown 
of Hes1 expression was associated with downregulation 
of conventional Notch1 targets genes as BCL2, BCL2L1, 
CDKN1A, CCDN1 and few of the of them were also 
validated by Western blots. DTK1, a positive regulator 
of Notch1 signaling, was evenly significantly affected, 
although its mechanism of action has been shown 
independent of the signaling pathway involving RBP-Jκ 
and Hes1/Hes5. Deltex1 and Notch1 (NICD1) regulate 
negatively neuronal differentiation of neural progenitor 
cells by inhibition of the transcriptional activation of bHLH 
transcription factor MASH1 [26].
CyclinD1, implicated in G1 progression, was 
surprisingly upregulated in shHes1-CSC. CyclinD1 is 
Figure 2: Targeting Hes1 expression induces morphological changes and negatively affects the cell cycle profile in 
shHes1-CSC. (A–C) Phase-contrast images captured at 200× magnification after 6hs and 48hs in growth conditions, reveal substantial 
cell changes with attachment of shHes1-CSC on plastic dishes and formation of neuron-like cells (arrows in B,C), contrary to pLKO.1 cells 
which formed classical not-adherent neurospheres. (D–F) FACS analyses of cell cycle profiles reveal a substantial shift from S phase to G1 
fraction of shHes1-CSC clones compared to pLKO.1 cells. Data of flow cytometry are representative of two independent experiments. The 
difference of percentages in cell cycle distribution between cell clones and p-LKO.1-CSC is consistent and can be considered biologically 
significant.
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a downstream target of multiple oncogenic pathways, 
e.g. Shh/Gli1 and Wnt/β-catenin [27,28]. Intrinsically 
unstable, CyclinD1 is regulated by the ubiquitin-
dependent proteasome system [29,30]. Besides, Hes1 is 
known to directly suppress Gli1 transcription, therefore 
upregulating CyclinD1, suggesting that targeting Notch1 
and Gli1 pathways simultaneously may be more effective 
to eliminate GBM cells [31]. 
Several evidence reported that in vivo hypoxia 
upregulated expression of Dll4, Jagged1, Notch1, 
Notch4, Hes1, and Hey which in turn promoted tumor 
angiogenesis [32, 33]. In addition, the upregulation of 
Dll4-Notch signaling components has been implicated in 
tumor angiogenesis but not in tumor growth [34]. Dll4 and 
Jagged1 may have opposing effects on tumor angiogenesis 
but a uniform prognostic effect in GBM [35]. Our results 
reported that the down-modulation of JAG1 and HEY1 
gene expression in shHes1-CSC (except for DLL1) 
correlated to a decrease of angiogenic markers CD31 and 
VE-Cadherin. 
In our study, a possible link between Notch/Hes1 
signaling and the control of GBM growth could be through 
modulation of Jak2/Stat3 signaling pathway. In glioma 
stem-like cells, arsenic trioxide (ATO) inhibited the 
phosphorylation and activation of Akt and Stat3 through 
Notch signaling blockade. These data show that the ATO is 
a promising new approach to decrease GBM proliferation 
and recurrence by downregulation of Notch pathway [36]. 
The phosphorylation state of Stat3 plays a crucial role in 
self-renewal and differentiation of neural stem cell and 
embryonic stem cells (ESC) as well as in tumorigenesis 
[37]. It has been demonstrated that Stat3-Y705 is 
crucial for self-renewal of mESC, instead Stat3-S727 is 
decisive in the transition from pluripotency to neuronal 
commitment of mESC [38]. In addition, Hes1 physically 
interacts with Stat3 protein enabling Jak2 to phosphorylate 
Stat3 [39]. Consistent with these reports, we showed a 
positive correlation between Stat3 phosphorylation and 
Notch/Hes1 pathways. Accordingly, Hes1 depletion 
resulted in a reduction of Stat3 phosphorylation at Y705 
and an increase at S727, which was accompanied by 
morphological modifications and appearance of MAP2 
positive cells in hHes1-CSC vs control cells. 
Constitutive activation of Stat3 and NF-κB 
signaling pathways regulate Notch pathway genes in 
GBM CSC [40]. Recent evidence reported that cAMP/
PKA enhances IL-1β induced-IL-6 synthesis through Jak2/
Stat3 activation, identifying novel therapeutic targets for 
the treatment of glioma [41]. Recent investigations report 
a crosstalk between inflammation and Notch1 signaling 
[42, 43] and highlight that inflammatory cytokines (IL1β, 
IL6, IL8 and p38 MAPK activity) are elevated in GBM 
[44]. In addition, in glioma-initiating cells and endothelial 
cells a new signaling PDGF-NOS2-ID4-miR129-Jagged 
Figure 3: Modulation of neural differentiation in shHes1-CSC by immunofluorescence assay. (A–C) Immunostaining for 
Nestin reveals its upregulation in control cells vs Hes1-depleted cells (arrows). (D–F) Immunostaining for MAP2 reveals its upregulation 
in Hes1-depleted cells vs control cells (arrows).  Images were captured at 400X magnification.
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has been discovered which drive to tumor progression 
[45]. Elevated NO synthase 2 (NOS2) expression 
correlates with decreased survival in human glioma 
patients [46]. Previously, we and others have demonstrated 
that NOS2 inhibition slowed colon and glioma stem cells 
growth in vivo animal models [47,46]. Accordingly, we 
report that targeting Hes1 downregulates NOS2, IL1B, 
IL6 and NF-κB2 mRNA levels. NF-κB2 (p100/p52), a 
member of the NF-κB/Rel family of transcription factors, 
is implicated in a variety of genes important for immune 
function. Our results suggest a link between Notch1/Hes1 
pathway and NF-kB2 gene regulation and corroborate 
Oswald’ results that reported that activated Notch1 
induced NF-κB2 promoter activity via a functional RBP-
Figure 4: Targeting Hes1 impairs cell invasive abilities, modulates Epithelial Mesenchymal Transition and inflammatory 
cytokines gene expression. (A) Addition of EGF promoted a significant migration of pLKO.1 cells in cell invasion assay compared to 
stem medium, contrary to that occurs in shHes1-CSC. PDGFAA and PDGFBB promoted a significant migration of shHes1-CSC clones 
in comparison to stem medium, instead pLKO.1-CSC are not significantly influenced by PDGFAA and PDGFBB. Error bars represent 
the mean ± SD of two independent experiments performed in triplicate. *P values < 0.05, **P < 0.01**, ***P < 0.001 vs. control stem 
medium were considered statistically significant. (B) RT-qPCR analyses of key genes for angiogenesis, EMT, immunomodulation and cell 
invasion. mRNA expression for cell-substrate molecules interaction (CDH1, CDH5) were drastically downmodulated in shHes1-CSC vs 
pLKO.1 cells. Few EMT markers (TWIST1, FN1, VIM), together with immunomodulators (NOS2, IL6, IL1B, IL23, NF-κB2) and matrix 
metalloproteinases (MMP7, MMP9) were similarly downmodulated in shHes1-CSC  in comparison to pLKO.1 cells.
Oncotarget8www.impactjournals.com/oncotarget
Jκ binding site [15]. In addition, the non-canonical NF-κB 
signaling has been shown to contribute to tumorigenesis 
through reactivation of TERT gene [16]. 
Other research groups reported that knockdown 
of Notch1 expression by siRNA in U251 glioma cells 
downregulated the expression of EGFR, indicating the 
crosstalk and interaction of Notch1 and EGFR signaling 
pathways [48]. Consistent with the above report, we 
demonstrated a repression of EGFR protein in shHes1-
CSC which justify their poor migration in response to 
EGF in cell invasion assay. Conversely, we noted an 
important upregulation of PDGFRβ in shHES1-CSC, but 
not for PDGFRα, that enable cell invasion in response to 
PDGF-BB and PDGF-AA respectively. This finding raises 
the issue that targeting Hes1 is not sufficient to impair 
CSC invasiveness features and suggest the need to correct 
the strategy of intervention. In fact, in our previous work, 
we stated that combination therapy either with anti-Notch/
anti-EGFR or anti-EGFR/anti-PDGFR drugs compared to 
therapy alone was more effective in reducing survival of 
c-CSC compared to p-CSC, suggesting that in the area 
of GBM peritumor tissue occurs a selection process, 
which results a more aggressive cell phenotype [17,18]. 
In fact, we earlier reported the upregulation, in p-CSC in 
comparison to c-CSC of several GBM samples, of drug 
resistance and/or EMT modulators such as TWIST, EDN1 
and PRKCA [18]. In line with this, in the current study we 
reported a significant down-modulation of mesenchymal 
genes FN1, VIM1 and TWIST1 that positively correlated 
to the inactivation of Notch1 and Stat3 signaling pathways 
in shHes1-CSC, suggesting further the primary role played 
by the association of Stat3 and Notch1 in mesenchymal 
GBM [5–8].
MAP/Erk, a well-studied signaling pathway, is 
involved in basic cell processes such as cell growth, 
differentiation, migration and apoptosis. Recently Zhang 
et al., reported that valproic acid was able to induce 
apoptosis in U87 glioma cells through activation of Erk 
and Akt pathways and GSK3β inhibition [49]. Similarly, 
we earlier reported the up-regulation of multiple 
oncogenic signals in PDGFRα-depleted GBM CSC, i.e., 
CyclinD1, Erk1/2 phosphorylation, EDN1, PDGF-C, 
Figure 5: Stat3/5 are critical factors for survival of CSC. (A) MTS assay was assessed to evaluate cells sensitivity to SH-4-
54, a Stat3/5 inhibitor. CSC undergone three doses of SH-4-54 (0.5–2–5 µM) and tested for cell vitality after 24 h of treatment. Data 
are represented as mean ± SD (n = 3) and are representative of three independent experiments. ***P < 0.001 vs control was considered 
highly significant. (B) Western blot analyses reported the effects of SH-4-54 on Caspase-3 activation and PARP1 cleavage (arrowheads). 
Deleterious effects were observed for Akt, Stat3 and Stat5 and Erk1/2 signaling pathways, Bcl2 and CyclinD1.  
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PDGF-D and PRKCB1 and so on. Simultaneously, we 
observed the start of neuronal differentiation, besides 
several detrimental effects on self-renewal, invasion, 
EMT and angiogenesis (Cenciarelli et al., 2016). In 
agreement with the just mentioned studies, we found that 
a marked activation of Erk1/2 in Hes1-depleted cells was 
linked to a significant reduction of proliferation rate and 
anti-apoptotic proteins expression (Bcl-2, Bcl-X), and 
finally the commitment toward neuronal differentiation. 
This behavior together with the upregulation of PDGFRβ 
and CyclinD1 might be a cell modality to survive and 
adapt to molecular changes induced by depletion of 
Hes1 and, therefore escape from apoptosis. Thus, further 
investigation of the crosstalk among PDGFR, CyclinD1 
and Erk1/2 signal transduction pathways is essential for 
elucidating the mechanism(s) underlying the phenomena 
observed in shHes1-CSC. 
The constitutive phosphorylation of Stat3 at 
Y705 seen in pLKO.1-CSC and its reduction following 
Hes1 depletion, prompted us to assess the effects of a 
pharmacological blockade of Stat3/5 on survival of 
GBM CSC. We succeeded to promote apoptosis in 
both cell populations through loss of Stat3 and Stat5 
proteins, besides a marked decline of p-Akt1 and 
p-Erk1/2 phosphorylation. Since shHes1-CSC displayed 
a less aggressive behavior respect to control cells, we 
assessed whether those cells would be more sensitive to 
Crenolanib (CR), a PDGFR inhibitor, respect to pLKO.1-
CSC. CR was able to induce apoptosis in control cells 
as earlier reported (Cenciarelli et al., 2014), but not in 
shHes1-CSC. This finding could be explained by the lack 
of effectiveness by CR on the constitutive oncogenic 
signals, which included PDGFRβ, Stat5, Erk1/2 and 
CyclinD1. Future investigations should pay attention 
to the multiple effects generated by anti-cancer drugs, 
and although those are developed for specific molecular 
targets, cells are able to find new modality to escape the 
drug’s effect.
MATERIAL AND METHODS 
Ethical statement
Procedures for collection of adult human GBM CSC 
were approved by the Ethical Committee of the Catholic 
University of Rome as reported previously [23]. Informed 
consent was obtained and all patients were fully aware of 
the aims and scope of this work. The ethical principles of 
the declaration of Helsinki were strictly followed. 
Cell culture and drug treatment of glioblastoma 
stem cells
We have used the same clinical materials reported 
in our previous papers [17, 23]. In brief, the CSC cells 
were retrieved from adult patients affected by GBM and 
undergoing craniotomy at the Institute of Neurosurgery, 
Catholic University-School of Medicine of Rome, Italy. 
Dissociated cells were cultured in the presence of human 
recombinant EGF (20 ng/ml; PeproTech, Rocky Hill, 
NJ), human recombinant bFGF (10 ng/ml; PeproTech), 
in DMEM/F12 (1:1) serum-free medium (Invitrogen, 
Carlsband, CA) as reported previously (Cenciarelli 
et al. 2014). Floating and adherent neurospheres were 
dissociated with Accutase at 37°C (Merck-Millipore). 
For the drug treatments, 5 µM of Crenolanib (CP-
8685596) and SH-4-54 (Selleckchem) were added for 
1 day.
shRNA, transfection and lentivirus production
The experiments of Hes1 RNA interference were 
performed using Mission Lentivirus-based shRNA 
(NM_005524.2-Sigma-Adrich). Lentivirus production 
was performed as reported previously [17]. We selected 
several puromycin resistant Hes1-directed shRNA 
cell clones. shHES1-CSC clone 7152 and 7153 were 
selected based on significant down-modulation of Hes1 
expression.
Western blots
GBM CSC are seeded as single cells (1 × 106/p90 
dish) in proliferation medium and collected 2–3 days 
later for Western blot analysis. Cells pellet were lysed 
for 30 min in 200 µl of lysis buffer (1% NP-40, 0.01% 
SDS, 20 mM Tris–HCl pH 7.4, 300 mM NaCl, 1 mM 
EDTA, 1 mM Na3VO4 and protease inhibitors cocktail 
from Sigma–Aldrich). Cells are ultrasonicated with 
two pulses of 5 sec at 50% of amplitude (Sonics and 
Materials, Newtown, CT). Equal amounts (30 µg/lane) 
of total protein extracts, quantified by Bio-Rad protein 
Assay (Bio-Rad, Munchen, Germany), were loaded on 
Bolt 4-12% Bis-Tris gels (Invitrogen), and transferred 
on Hybond-P Extra membrane (Amersham Biosciences, 
GE Healthcare). Filters were immunoblotted using the 
following primary antibodies: goat anti-PDGFRα and 
mouse anti-β-actin (SIGMA), rabbit anti-EGFR, anti-
PDGFRβ, anti-T202/Y204-ERK1/2, anti-ERK1/2, 
anti-Y705-STAT3, anti-S727-STAT3, anti-STAT3, anti-
STAT5,  and anti-Caspase-3 (all purchased from Cell 
Signaling, USA), mouse anti-S473-AKT1 and rabbit anti-
AKT1 (Calbiochem), mouse anti-BCL2 (Dako), mouse 
anti-Nestin  (Millipore), mouse anti-GFAP (Covance), 
and mouse anti-βTubIII (Chemicon), mouse anti-MAP2 
(a/b) (Millipore), mouse anti-BCL2 (DAKO), goat anti-
VE-CAD, rabbit anti-CD31, anti-BCL-X/L, anti-CycD1, 
anti-p27, anti-SOX2  and anti-PARP1 (all purchased from 
Santa Cruz-USA), rabbit anti-Survivin (Abcam). After 
three washing with TBS-Tween buffer, immuno-reactive 
proteins were detected using rabbit anti-mouse, donkey-
anti-rabbit and donkey anti-goat horseradish peroxidase-
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conjugated secondary antibodies directed to the 
appropriate primary antibodies (Jackson Immunoresearch 
Laboratories, West Grove, PA). The proteins were 
then visualized using the chemiluminescence system 
(Millipore). Gels and Images acquisition was done by HP 
Photosmart Essential Ver. 1.12 and Adobe Photoshop CS5 
respectively. 
Cell proliferation and cytotoxicity assays
We used the CellTiter 96 Aqueous One Solution 
Reagent (Promega), a cell proliferation colorimetric 
assay containing a novel tetrazolium compound 
MTS. shHES1-CSC cells vs control cells (pLKO.1) 
are dissociated into single cells and 2 × 104 cells/
well plated in triplicate on 6-well dishes. Cells were 
harvested and counted at different time points in growth 
medium, considering the starting time the day after 
plating. For pharmacological studies, 5 × 104 cells/well 
were plated in triplicate for each group on 12-well 
plates and treated for 1 day with the drugs or DMSO-
vehicle. The metabolically active cells reduced MTS 
into a soluble formazan product, whose absorbance 
is measured at 490 nm in a plate reader (Bio-Rad). 
These experiments were performed twice and each 
time in triplicate. The absorbance values of the 
collected samples were subtracted from the background 
absorbance of medium-only control and expressed as 
mean average ± SD (n = 3). 
Immunocytochemistry
Cell populations were dissociated with Pasteur 
pipettes and plated onto Matrigel GFR-coated glass 
coverslips (BD-Italia) to perform the immunostaining. 
Cells were fixed in 4% paraformaldehyde and 
permeablized with 0.2% Triton-100 and subsequently 
processed for immunolabeling. The following primary 
antibodies (Ab) were used: mouse anti-MAP2 (a/b), and 
rabbit anti-Nestin (Millipore). The secondary Ab used 
were: fluorescein isothiocyante (FITC) affinity purified 
goat anti-rabbit and Tetramethyl rhodamine isothiocyanate 
(TRITC) affinity purified donkey anti-mouse (Chemicon). 
Nuclei were stained with Hoechst 33258 diluted in PBS 
(0,2 µg/ml; SIGMA). Cells were photographed at 400X 
magnification using a fluorescent microscope (Olympus 
microscope OLYMPUS Bx5 with Spot CCD Camera). 
A quantitative cell analysis was performed by counting 
for each antibody used almost 100 cells/field of five fields 
from each of three independent experiments.
RT-qPCR assay
Total RNA was extracted using Triazol and by 
RNeasy mini kit (Qiagen, USA). cDNAs were obtained 
using QuantiTect Reverse Transcription kit (Qiagen, 
USA). Quantitative Real Time Reverse Transcriptase 
PCR (RT-qPCR) was conducted using SYBR Hi-ROX 
kit (Bioline, UK). RT-qPCR was performed by 7900HT 
instrument equipped with SDS2.2 software (Applied 
Biosystems, CA). The sequences of oligonucleotides used 
for RT-qPCR were described in Table 1. Relative levels 
of gene expression (-∆Ct), were normalized respect to 
housekeeping genes (GAPDH, TBP) by using the ∆Ct 
method following manufacturer’s guide.
Cell invasion assay
For the invasion assay, 1 × 105 cells were loaded in 
0.3 ml of Stem Medium in triplicate into the top chamber 
of 150 µl matrigel-coated transwell insert (Millipore). The 
bottom wells contained 0.4 ml of stem medium as control 
or medium plus chemoattractant (EGF or PDGF-AA 
or PDGF-BB). After three days, cells on the top surface 
of the filter are removed with a cottonswab. Thereafter, 
the filters were fixed and stained with crystal violet and 
subsequently washed to collect the staining solution. 
OD values, proportional to the number of cells, were 
measured on a plate reader by a 590 nm filter (Bio-Rad). 
These experiments were performed twice and each time 
in triplicate. The absorbance values were calculated as 
mean ± SD (n = 3). 
FACS analysis
Cells were fixed with 0.5 ml of cold Methanol/
Acetone Solution (1:5) and left at 4°C for at least 1 hour, 
then centrifuged at 950 RPM for 5 minutes. The cell pellet 
was resuspended in 100 µl of PBS, 375ul of RNAse A 
(100 µg/ml) and 25 µl of Propidium Iodide (1 mg/ml). 
Cells were incubated at room temperature for 15 minutes 
and left in the dark at 4°C until FACS analysis. Samples 
were acquired on FacsCalibur (BD Becton Dickinson) 
at 488 nm. The acquired FACS data were analyzed by 
ModFit LT software (Verity Software House, Inc.) to 
determine the percentage of cells sub G1, G1, S and G2 
/M phases. These experiments were performed twice for 
each sample.
Statistical analysis
Statistical analysis was performed with Prism5 
(GraphPad) and Microsoft Office Excel 2013. All 
data shown are representative of results obtained from 
experiments conducted two or three times as specified 
in the specific sections. The results were analyzed by 
Two-way ANOVA and Bonferroni’s posttests. Data are 
expressed as mean ± standard deviation (SD) and P values 
≤ 0.05 (*), ≤ 0.01(**), ≤ 0.001 (***) were considered 
statistically significant. 
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Table 1: List of primers for RT-PCR analysis
Gene ID Name Sequences 5ʹ      3ʹ
NM_005524.3 hHES1 For AAGAAAGATAGCTCGCGGCA
Rev CGGAGGTGCTTCACTGTCAT
NM_001040708.1 hHEY1 For AGGCTGGTACCCAGTGCTT
Rev GCATTCCCGAAATCCCAAACT
NM_000214.2 hJAG1 For ATGGGCCCCGAATGTAACAG
Rev ATCACAGTACAGGCCTTGCC
NM_017617.4 hNOTCH1 For CACTGCGAGGTCAACACAGA
Rev GTCCACATCGTACTGGCACA
NM_005618.3 hDLL1 For GGAGAAAGTGTGCAACCCTG
Rev CCCACTCTGCACTTGCATTC
NM_001317172.1 hDLK1 For TTCACCGCAAGAGGATTCCC
Rev GTTGGACGTGCCGATAGTGA
NM_053056.2 hCCDN1 For CAGATCATCCGCAAACACGC
Rev ATGGAGGGCGGATTGGAAAT
NM_000389.4 hCDKN1A For TGCCGAAGTCAGTTCCTT
Rev CATTAGCGCATCACAGTC
NM_000633.2 hBCL2 For CTTTGAGTTCGGTGGGGTCA
Rev GGGCCGTACAGTTCCACAAA
NM_001191.3 hBCL2L1 For AGCTTTGAACAGGATACTTTTGTGG
Rev GGTGGGAGGGTAGAGTGGAT
NM_001077494.3 hNF-κB2 For GGCCGGGACAAGAGAAAAGA
Rev CCAGAATTTTAGACGCCCGC
NM_000625.4 hNOS2 For TGAACTACGTCCTGTCCCCT
Rev CTCTTCTCTTGGGTCTCCGC
NM_000600.4 hIL6 For TTCGGTACATCCTCGACGGC
Rev CAGTGCCTCTTTGCTGCTTTC
NM_000576.2 hIL1B For AGCTGATGGCCCTAAACAGAT
Rev TGGTCGGAGATTCGTAGCTG
NM_016584.2 hIL23A For CCGCTTCAAAATCCTTCGCA
Rev CTGCCTTTAGGGACTCAGGG
NM_002423.4 hMMP7 For AGAGATCCCCCTGCATTTCA
Rev GGCCCATCAAATGGGTAGGAG
NM_004994.2 hMMP9 For CGACGTCTTCCAGTACCGAG
Rev TTGTATCCGGCAAACTGGCT
NM_003380.3 hVIM For AGAGGAAGCCGAAAACACCC
Rev TCAAGGTCAAGACGTGCCAG 
NM_000474.3 hTWIST For TCAAGAGGTCGTGCCAATCA
Rev ATGGTTTTGCAGGCCAGTTT
NM_001306132.1 hFN1 For TGACAAGCAGACCAGCTCAG
Rev CTGTCACACGAGCCCTTCTT 
NM_001795.3 hCDH5 For ATGCGGCTAGGCATAGCATT
Rev TGTGACTCGGAAGAACTGGC
NM_004360.3 hCDH1 For CGAGAGCTACACGTTCACGG
Rev CTTTGTCGACCGGTGCAATC
NM_001172085.1 hTBP For GAACATCATGGATCAGAACAACA
Rev ATAGGGATTCCGGGAGTCAT
NM_001256799.2 hGAPDH For AGCCACATCGCTCAGACA
Rev GCCCAATACGACCAAATCC
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CONCLUSIONS 
We used shRNA to knockdown Hes1 expression in 
GBM CSC to understand its mechanism(s) of action and 
make available further therapeutic targets against GBM. 
Our findings provide the rationale for possible targeting of 
Notch pathway through inhibition of Hes1, which would 
be beneficial in modulation of the cell growth and invasive 
ability of GBM CSC, but not sufficient to induce CSC 
apoptosis. To conclude, we suggest that a Stat targeted 
therapy, would provide more therapeutic effects than an 
anti-Notch/Hes1 drug intervention.
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